PPCB Stock Forecast: Propanc Biopharma, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 45 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Propanc Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.
Revisions (20): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PPCB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PPCB, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
PPCB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PPCB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.3×
- EV / EBITDA
- —
Cheaper than 93% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −211.0%
- Return on assets
- −97.5%
- Dividend yield
- —
Higher than 7% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Propanc Biopharma, Inc. has a market value of $1.8M and an enterprise value of $2.0M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$18.4M.
Free cash flow in the twelve months to 31 Mar 2026: −$4.1M.
Propanc Biopharma, Inc. employs 2 people.
Data provided by Twelve Data
PPCB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PPCB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Propanc Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PPCB
How does Ticker Nerd's model rank PPCB?
As at 21 Nov 2026, Propanc Biopharma, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).
What is the PPCB stock forecast for 2030?
No analyst covering Propanc Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PPCB are extrapolating price history, which says nothing about the business.
What does Propanc Biopharma, Inc. do?
Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments for patients with pancreatic, ovarian, and colorectal cancers. The company’s current work centers on proenzyme-based therapies designed to address recurring and metastatic disease, with an emphasis on helping control tumor spread and reduce recurrence.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments for patients with pancreatic, ovarian, and colorectal cancers. The company’s current work centers on proenzyme-based therapies designed to address recurring and metastatic disease, with an emphasis on helping control tumor spread and reduce recurrence. Its product pipeline includes lead candidates such as PRP and POP1, which are being developed as long-term therapeutic options for solid tumors. Propanc Biopharma operates in the oncology-focused biotechnology segment of the life sciences market, where it contributes to the development of novel approaches for chronic and advanced cancer care. Headquartered in Camberwell, Australia, the company is positioned as a specialized developer of experimental cancer therapies for use in clinical and preclinical settings.
CEO Mr. James Nathanielsz · 2 employees · Australia · https://www.propanc.com